2-(4-Fluorophenyl)-5-[(5-iodo-2-methylphenyl)methyl]thiophene CAS 898566-17-1 Puritas >98.0% (HPLC)

Description:

Nomen chemicum: 2-(4-Fluorophenyl) -5-[(5-iodo-2-methylphenyl)methyl]thiophene

CAS: 898566-17-1

Puritas: >98.0% (HPLC)

Aspectus: Crystallinus Pulvis albus ad pallide Yellow

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Manufacturer Supple intermedia:
4-Acidum Fluorophenylboronicum CAS: 1765-93-1
2-(4-Fluorophenyl)thiophene CAS: 58861-48-6
2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone CAS: 32384-65-9
5-Iodo-2-Methylbenzoicum Acidum CAS 54811-38-0
2-(5-Bromo-2-methylbenzyl)-5-(4-fluorophenyl)thiophene CAS: 1030825-20-7
2-(4-Fluorophenyl) -5-[(5-iodo-2-methylphenyl)methyl]thiophene CAS: 898566-17-1
CAS: 842133-18-0
CAS: 928672-86-0

Chemical Properties:

Nomen chemicum	2-(4-Fluorophenyl) -5-[(5-iodo-2-methylphenyl)methyl]thiophene
CAS Number	898566-17-1
CATTUS Number	RF-PI1501
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C18H14FIS
M. Pondus	408.27
Liquescens punctum	109.0~11.0
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba ad luteum Crystallinum pulveris
Puritas / Analysis Methodus	>98.0% (HPLC)
Damnum in Siccatio	<1.00%
Totalis immunditias	<2.00%
Test Standard	Enterprise Standard

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

FAQ:

Applicatio:

2-(4-Fluorophenyl) -5-[(5-iodo-2-methylphenyl)methyl]thiophene (CAS: 898566-17-1) est agens antidiabeticum et medium API (CAS: 842133-18-0) .(CAS: 842133-18-0) sodium/glucosum cotransporter 2 (SGLT2) inhibitor et candidatus ad curationem diabete et dolore magnae 2 generis.(CAS: 842133-18-0) Medicamentum orale cottidianum semel est, quod operatur inhibendo sodium glucosum co-portatorium 2 (SGLT2) tamquam novum medicamentum.(CAS: 842133-18-0) Glucosum sanguinem demittere potest, sanguinem glucosum reabsorptionem renum interdicere et excretionem sanguinis glucosi in urina augere.Inhibitor FDA probatus est primus pro GLT2 et adultos aegros cum diabete specie II tractare solebat.